Advertisement

Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia

Published:February 05, 2018DOI:https://doi.org/10.1016/j.jns.2018.02.014

      Abstract

      Although VMAT2-inhibitors are now established as first-line treatment for tardive dyskinesia, not all patients respond to, or tolerate them. Numerous other agents have been adopted to treat tardive dyskinesia, but with variable results and generally lower quality methodologic reports. Amantadine is the most promising but benzodiazepines, branched chain neutral amino acids, Vitamin B6, several nutraceuticals, and botulinum toxin injections might help some patients. In all cases, better placebo controlled trials are needed before definitive recommendations can be made.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hauser R.A.
        • Factor S.A.
        • Marder S.R.
        • Knesevich M.A.
        • Ramirez P.M.
        • Jimenez R.
        • Burke J.
        • Liang G.S.
        • O'Brien C.F.
        KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia.
        Am. J. Psychiatry. 2017; 174: 476-484
        • Anderson K.E.
        • Stamler D.
        • Davis M.D.
        • Factor S.A.
        • Hauser R.A.
        • Isojärvi J.
        • Jarskog L.F.
        • Jimenez-Shahed J.
        • Kumar R.
        • McEvoy J.P.
        • Ochudlo S.
        • Ondo W.G.
        • Fernandez H.H.
        Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
        Lancet Psychiatry. 2017; 4: 595-604
        • Fernandez H.H.
        • Factor S.A.
        • Hauser R.A.
        • Jimenez-Shahed J.
        • Ondo W.G.
        • Jarskog L.F.
        • Meltzer H.Y.
        • Woods S.W.
        • Bega D.
        • LeDoux M.S.
        • Shprecher D.R.
        • Davis C.
        • Davis M.D.
        • Stamler D.
        • Anderson K.E.
        Randomized controlled trial of deutetrabenazine for tardive dyskinesia.
        Neurology. 2017; 88: 2003-2010
        • Gunne L.M.
        • Häggström J.E.
        • Sjöquist B.
        Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis.
        Nature. 1984; 309: 347-349
        • Grimm J.W.
        • Chapman M.A.
        • Zahm D.S.
        • See R.E.
        Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats.
        Synapse. 2001; 39: 51-57
        • Zhou F.-M.
        • Wilson C.
        • Dani J.A.
        Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems.
        Neuroscience. 2003; 9: 23-36
        • Cadet J.L.
        • Lohr J.B.
        Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E.
        Ann. N. Y. Acad Sci. 1989; 570: 176-185
        • Cadet J.L.
        • Kahler L.A.
        Free radical mechanisms in schizophrenia and tardive dyskinesia.
        Neurosci. Biobehav. Rev. 1994; 18: 457-467
        • Flood J.
        • Ph D.
        • Baer L.
        • Coyle J.T.
        Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
        Psychiatry Interpers. Biol. Process. 1998; : 1207-1213
        • Davies W.L.
        • Grunert R.R.
        • Haff R.F.
        • McGahen J.W.
        • Neumayer E.M.
        • Paulshock M.
        • Watts J.C.
        • Wood T.R.
        • Hermann E.C.
        • Hoffmann C.E.
        Antiviral activity of 1-adamantanamine (Amantadine).
        Science. 1964; 144: 862-863
        • Kelly J.T.
        • Abuzzahab F.S.
        The antiparkinson properties of amantadine in drug-induced Parkinsonism.
        J. Clin. Pharmacol. New Drugs. 1971; 11: 211-214
        • Consolo S.
        • Ladinsky H.
        • Garattini S.
        Effect of several dopaminergic drugs and trihexyphenidyl on cholinergic parameters in the rat striatum.
        J. Pharm. Pharmacol. 1974; 26: 275-277
        • Kornhuber J.
        • Bormann J.
        • Hübers M.
        • Rusche K.
        • Riederer P.
        Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.
        Eur. J. Pharmacol. 1991; 206: 297-300
        • Vale S.
        • Espejel M.A.
        Amantadine for dyskinesia tarda.
        N. Engl. J. Med. 1971; 284: 673
        • Decker B.L.
        • Davis J.M.
        • Jonowsky D.S.
        • El-Yousef M.K.
        • Sekerke H.J.
        Amantadine hydrochloride treatment of tardive dyskinesia.
        N. Engl. J. Med. 1971; 285: 860
        • Janowsky D.S.
        • El-Yousef M.K.
        • Davis J.M.
        • Sekerke H.J.
        • Morris D.R.
        • Decker B.
        Effects of amantadine on tardive dyskinesia and pseudo-parkinsonism.
        N. Engl. J. Med. 1972; 286: 785
        • DiMascio A.
        • Bernardo D.L.
        • Greenblatt D.J.
        • Marder J.E.
        A controlled trial of amantadine in drug-induced extrapyramidal disorders.
        Arch. Gen. Psychiatry. 1976; 33: 599-602
        • Silver H.
        • Geraisy N.
        • Schwartz M.
        No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind cross-over, placebo-controlled study in medicated chronic schizophrenic patients.
        J. Clin. Psychiatry. 1995; 56: 167-170
        • Angus S.
        • Sugars J.
        • Boltezar R.
        • Koskewich S.
        A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia.
        J. Clin. Psychopharmacol. 1997; 17: 88-91
        • Pappa S.
        • Tsouli S.
        • Apostolou G.
        • Mavreas V.
        • Konitsiotis S.
        Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.
        Clin. Neuropharmacol. 2010; 33: 271-275
        • Bhidayasiri R.
        • Fahn S.
        • Weiner W.J.
        • Gronseth G.S.
        • Sullivan K.L.
        • Zesiewicz T.A.
        Evidence-based guideline: treatment of tardive syndromes.
        Neurology. 2013; 81: 463-469
        • Hattori T.
        • McGeer P.L.
        • Fibiger H.C.
        • McGeer E.G.
        On the source of GABA-containing terminals in the substantia nigra. Electron microscopic autoradiographic and biochemical studies.
        Brain Res. 1973; 54: 103-114
        • Macdonald R.L.
        • Olsen R.W.
        GABAA receptor channels.
        Ann. Rev. Neurosci. 1994; 17: 569-602
        • Campo-Soria C.
        • Chang Y.
        • Weiss D.S.
        Mechanism of action of benzodiazepines on GABAA receptors.
        Br. J. Pharmacol. 2006; 148: 984-990
        • Hill D.R.
        • Bowery N.G.
        3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABA B sites in rat brain.
        Nature. 1981; 290: 149-152
        • Kerr D.I.
        • Ong J.
        GABAB receptors.
        Pharmacol. Ther. 1995; 67: 187-246
        • Thaker G.K.
        • Nguyen J.A.
        • Strauss M.E.
        • Jacobson R.
        • Kaup B.A.
        • Tamminga C.A.
        Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy.
        Am. J. Psychiatry. 1990; 147: 445-451
        • Cassady S.L.
        • Thaker G.K.
        • Summerfelt A.
        • Tamminga C.A.
        The Maryland Psychiatric Research Center scale and the characterization of involuntary movements.
        Psychiatry Res. 1997; 70: 21-37
        • Druckman R.
        • Seelinger D.
        • Thulin B.
        Chronic involuntary movements induced by phenothiazines.
        J. Nerv. Ment. Dis. 1962; 135: 69-76
        • Singh M.M.
        • Becker R.E.
        • Pitman R.K.
        • Nasrallah H.A.
        • Lal H.
        • Dufresne R.L.
        • Weber S.S.
        • McCalley-Whitters M.
        Diazepam-induced changes in tardive dyskinesia: suggestions for a new conceptual model.
        Biol. Psychiatry. 1982; 17: 729-742
        • Singh M.M.
        • Becker R.E.
        • Pitman R.K.
        • Nasrallah H.A.
        • Lal H.
        Sustained improvement in tardive dyskinesia with diazepam: indirect evidence for corticolimbic involvement.
        Brain Res. Bull. 1983; 11: 179-185
        • Weber S.S.
        • Dufresne R.L.
        • Becker R.E.
        • Mastrati P.
        Diazepam in tardive dyskinesia.
        Drug Intell. Clin. Pharm. 1983; 17: 523-527
        • Csernansky J.G.
        • Tacke U.
        • Rusen D.
        • Hollister L.E.
        The effect of benzodiazepines on tardive dyskinesia symptoms.
        J. Clin. Psychopharmacol. 1988; 8: 154-155
        • Vasavan Nair N.P.
        • Yassa R.
        • Ruiz Navarro J.
        • Schwartz G.
        Baclofen in the treatment of tardive dyskinesia.
        Am. J. Psychiatry. 1978; 135: 1562-1563
        • Gerlach J.
        • Rye T.
        • Kristjansen P.
        Effect of baclofen on tardive dyskinesia.
        Psychopharmacology. 1978; 56: 145-151
        • Stewart R.M.
        • Rollins J.
        • Beckham B.
        • Roffman M.
        Baclofen in tardive dyskinesia patients maintained on neuroleptics.
        Clin. Neuropharmacol. 1982; 5: 365-373
        • Glazer W.M.
        • Moore D.C.
        • Bowers M.B.
        • Bunney B.S.
        • Roffman M.
        The treatment of tardive dyskinesia with baclofen.
        Psychopharmacology. 1985; 87: 480-483
        • Davis K.L.
        • Berger P.A.
        • Hollister L.E.
        Choline for tardive dyskinesia.
        N. Engl. J. Med. 1975; 293: 152
        • Caroff S.N.
        • Campbell E.C.
        • Havey J.
        • Sullivan K.A.
        • Mann S.C.
        • Gallop R.
        Treatment of tardive dyskinesia with donepezil: a pilot study.
        J. Clin. Psychiatry. 2001; 62: 772-775
        • De Montigny C.
        • Chouinard G.
        • Annable L.
        Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study.
        Psychopharmacology (Berlin). 1979; 65: 219-223
        • George J.
        • Pridmore S.
        • Aldous D.
        Double blind controlled trial of deanol in tardive dyskinesia.
        Aust. New Zeal. J. Psychiatry. 1981; 15: 68-71
        • Davis K.L.
        • Hollister L.E.
        • Barchas J.D.
        • Berger P.A.
        Choline in tardive dyskinesia and Huntington's disease.
        Life Sci. 1976; 19: 1507-1515
        • Jackson I.V.
        • Nuttall E.A.
        • Ibe I.O.
        • Perez-Cruet J.
        Treatment of tardive dyskinesia with lecithin.
        Am. J. Psychiatry. 1979; 136: 1458-1460
        • Gelenberg A.J.
        • Dorer D.J.
        • Wojcik J.D.
        • Falk W.E.
        • Brotman A.W.
        • Leahy L.
        A cross-over study of lecithin treatment of tardive dyskinesia.
        J. Clin. Psychiatry. 1990; 51: 149-153
        • Izumi K.
        • Tominaga H.
        • Koja T.
        • Nomoto M.
        • Shimizu T.
        • Sonoda H.
        • Imamura K.
        • Igata A.
        • Fukuda T.
        Meclofenoxate therapy in tardive dyskinesia: a preliminary report.
        Biol. Psychiatry. 1986; 21: 151-160
        • Ingram N.A.
        • Newgreen D.B.
        The use of tacrine for tardive dyskinesia.
        Am. J. Psychiatry. 1983; 140: 1629-1631
        • Tammenmaa I.
        • McGrath J.
        • Sailas E.E.
        • Soares-Weiser K.
        Cholinergic medication for neuroleptic-induced tardive dyskinesia.
        Cochrane Database Syst. Rev. 2002; : CD000207
        • Tammenmaa I.A.
        • Sailas E.
        • McGrath J.J.
        • Soares-Weiser K.
        • Wahlbeck K.
        Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials.
        Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2004; 28: 1099-1107
        • Caroff S.N.
        • Walker P.
        • Campbell C.
        • Lorry A.
        • Petro C.
        • Lynch K.
        • Gallop R.
        Treatment of tardive dyskinesia with galantamine: a randomized controlled cross-over trial.
        J. Clin. Psychiatry. 2007; 68: 410-415
        • Shi J.
        • Tan Y.L.
        • Wang Z.R.
        • An H.M.
        • Li J.
        • Wang Y.C.
        • Lv M.H.
        • Yan S.X.
        • Wu J.Q.
        • Soares J.C.
        • DeYang F.
        • Zhang X.Y.
        Ginkgo biloba and vitamin E ameliorate haloperidol-induced vacuous chewingmovement and brain-derived neurotrophic factor expression in a rat tardive dyskinesia model.
        Pharmacol. Biochem. Behav. 2016; 148: 53-58
        • An H.M.
        • Tan Y.L.
        • Shi J.
        • Wang Z.
        • Lv M.H.
        • Soares J.C.
        • Zhou D.
        • Yang F.
        • Zhang X.Y.
        Ginkgo biloba leaf extract and alpha-tocopherol attenuate haloperidol-induced orofacial dyskinesia in rats: possible implication of antiapoptotic mechanisms by preventing Bcl-2 decrease and Bax elevation.
        Phytomedicine. 2016; 23: 1653-1660
        • Ink S.L.
        • Henderson L.M.
        Vitamin B6 metabolism.
        Ann. Rev. Nutr. 1984; 4: 455-470
        • Komatsu S.
        • Yanaka N.
        • Matsubara K.
        • Kato N.
        Antitumor effect of vitamin B6 and its mechanisms.
        Biochim. Biophys. Acta. 2003; 1647: 127-130
        • Kannan K.
        • Jain S.K.
        Effect of vitamin B 6 on oxygen radicals, mitochondrial membrane potential, and lipid peroxidation in H2O2 -treated U937 monocytes.
        Free Radic. Biol. Med. 2004; 36: 423-428
        • Lerner V.
        • Kaptsan A.
        • Miodownik C.
        • Kotler M.
        Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study.
        Clin. Neuropharmacol. 1999; 22: 241-243
        • Gharabawi G.M.
        • Bossie C.A.
        • Lasser R.A.
        • Turkoz I.
        • Rodriguez S.
        • Chouinard G.
        Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia.
        Schizophr. Res. 2005; 77: 119-128
        • Lerner V.
        • Miodownik C.
        • Kaptsan A.
        • Cohen H.
        • Matar M.
        • Loewenthal U.
        • Kotler M.
        Vitamin B 6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, cross-over study.
        Am. J. Psychiatry. 2001; 158: 1511-1514
        • Lerner V.
        • Miodownik C.
        • Kaptsan A.
        • Bersudsky Y.
        • Libov I.
        • Sela B.
        • Witztum E.
        Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, cross-over study.
        Psychiatry Interpers. Biol. Process. 2007; : 25-30
        • Schaumburg H.
        • Kaplan J.
        • Windebank A.
        • Vick N.
        • Rasmus S.
        • Pleasure D.
        • Brown M.J.
        Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome.
        N. Engl. J. Med. 1983; 309: 445-448
        • Scott K.
        • Zeris S.
        • Kothari M.J.
        Elevated B6 levels and peripheral neuropathies.
        Electromyogr. Clin. Neurophysiol. 2008; 48: 219-223
        • Lohr J.B.
        • Cadet J.L.
        • Lohr M.A.
        • Jeste D.V.
        • Wyatt R.J.
        Alpha-tocopherol in tardive dyskinesia.
        Lancet. 1987; 1: 913-914
        • Elkashef A.M.
        • Ruskin P.E.
        • Bacher N.
        • Barrett D.
        Vitamin E in the treatment of tardive dyskinesia.
        Am. J. Psychiatry. 1990; 147: 505-506
        • Egan M.F.
        • Hyde T.M.
        • Albers G.W.
        • Elkashef A.
        • Alexander R.C.
        • Reeve A.
        • Blum A.
        • Saenz R.E.
        • Wyatt R.J.
        Treatment of tardive dyskinesia with vitamin E.
        Am. J. Psychiatry. 1992; 149: 773-777
        • Adler L.A.
        • Peselow E.
        • Rotrosen J.
        • Duncan E.
        • Lee M.
        • Rosenthal M.
        • Angrist B.
        Vitamin E treatment of tardive dyskinesia.
        Am. J. Psychiatry. 1993; 150: 1405-1407
        • Lohr J.B.
        • Caligiuri M.P.
        A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
        J. Clin. Psychiatry. 1996; 57: 167-173
        • Shriqui C.L.
        • Bradwejn J.
        • Annable L.
        • Jones B.D.
        Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study.
        Am. J. Psychiatry. 1992; 149: 391-393
        • Lam L.C.
        • Chiu H.F.
        • Hung S.F.
        Vitamin E in the treatment of tardive dyskinesia: a replication study.
        J. Nerv. Ment. Dis. 1994; 182: 113-114
        • Adler L.A.
        • Rotrosen J.
        • Edson R.
        • Lavori P.
        • Lohr J.
        • Hitzemann R.
        • Raisch D.
        • Caligiuri M.
        • Tracy K.
        Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group.
        Arch. Gen. Psychiatry. 1999; 56: 836-841
        • Soares-Weiser K.
        • Maayan N.
        • McGrath J.
        Vitamin E for neuroleptic-induced tardive dyskinesia.
        Cochrane Database Syst. Rev. 2011; : CD000209
        • Zhou Z.
        • Zheng S.
        The missing link in Ginkgo evolution.
        Nature. 2003; 423: 821-822
        • Zhang W.F.
        • Tan Y.L.
        • Zhang X.Y.
        • Chan R.C.K.
        • Wu H.R.
        • Zhou D.F.
        Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial.
        J. Clin. Psychiatry. 2011; 72: 615-621
        • Garfinkel D.
        • Laudon M.
        • Nof D.
        • Zisapel N.
        Improvement of sleep quality in elderly people by controlled-release melatonin.
        Lancet. 1995; 346: 541-544
        • Pieri C.
        • Marra M.
        • Moroni F.
        • Recchioni R.
        • Marcheselli F.
        Melatonin: a peroxyl radical scavenger more effective than vitamin E.
        Life Sci. 1994; 55: PL271-6
        • Shamir E.
        • Barak Y.
        • Plopsky I.
        • Zisapel N.
        • Elizur A.
        • Weizman A.
        Is melatonin treatment effective for tardive dyskinesia?.
        J. Clin. Psychiatry. 2000; 61: 556-558
        • Shamir E.
        Melatonin treatment for tardive dyskinesia.
        Arch. Gen. Psychiatry. 2001; 58: 1049-1052
        • Egashira N.
        • Nogami A.
        • Iwasaki K.
        • Ishibashi A.
        • Uchida N.
        • Takasaki K.
        • Mishima K.
        • Nishimura R.
        • Oishi R.
        • Fujiwara M.
        Yokukansan enhances pentobarbital-induced sleep in socially isolated mice: possible involvement of GABA(A)-benzodiazepine receptor complex.
        J. Pharmacol. Sci. 2011; 116: 316-320
        • Ueki T.
        • Mizoguchi K.
        • Yamaguchi T.
        • Nishi A.
        • Sekiguchi K.
        • Ikarashi Y.
        • Kase Y.
        Yokukansan, a traditional Japanese medicine, decreases head-twitch behaviors and serotonin 2A receptors in the prefrontal cortex of isolation-stressed mice.
        J. Ethnopharmacol. 2015; 166: 23-30
        • Shimada Y.
        • Goto H.
        • Itoh T.
        • Sakakibara I.
        • Kubo M.
        • Sasaki H.
        • Terasawa K.
        Evaluation of the protective effects of alkaloids isolated from the hooks and stems of Uncaria sinensis on glutamate-induced neuronal death in cultured cerebellar granule cells from rats.
        J. Pharm. Pharmacol. 1999; 51: 715-722
        • Zhao Y.-R.
        • Qu W.
        • Liu W.-Y.
        • Hong H.
        • Feng F.
        • Chen H.
        • Xie N.
        YGS40, an active fraction of yi-gan san, reduces hydrogen peroxide-induced apoptosis in PC12 cells.
        Chin. J. Nat. Med. 2015; 13: 438-444
        • Miyaoka T.
        • Furuya M.
        • Yasuda H.
        • Hayashida M.
        • Nishida A.
        • Inagaki T.
        • Horiguchi J.
        Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
        Prog. Neuro-Psychopharmacol. Bio Psychiatry. 2008; 32: 761-764
        • Chan H.-Y.
        • Chiang S.-C.
        • Chang C.-J.
        • Gau S.S.-F.
        • Chen J.-J.
        • Chen C.-H.
        • Hwu H.-G.
        • Lai M.-S.
        A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
        J. Clin. Psychiatry. 2010; 71: 1226-1233
        • Durif F.
        • Debilly B.
        • Galitzky M.
        • Morand D.
        • Viallet F.
        • Borg M.
        • Thobois S.
        • Broussolle E.
        • Rascol O.
        Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study.
        Neurology. 2004; 62: 381-388
        • Grover S.
        • Hazari N.
        • Kate N.
        • Chakraborty K.
        • Sharma A.
        • Singh D.
        • Gupta J.
        • Lahariya S.
        Management of tardive syndromes with clozapine: a case series.
        Asian J. Psychiatr. 2014; 8: 111-114
        • Lynch B.A.
        • Lambeng N.
        • Nocka K.
        • Kensel-Hammes P.
        • Bajjalieh S.M.
        • Matagne A.
        • Fuks B.
        The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
        Proc. Natl. Acad. Sci. 2004; 101: 9861-9866
        • Custer K.L.
        Synaptic vesicle protein 2 enhances release probability at quiescent synapses.
        J. Neurosci. 2006; 26: 1303-1313
        • Chang W.-P.
        • Sudhof T.C.
        SV2 renders primed synaptic vesicles competent for Ca2+−induced exocytosis.
        J. Neurosci. 2009; 29: 883-897
        • McGavin C.L.
        • John V.
        • Musser W.S.
        Levetiracetam as a treatment for tardive dyskinesia: a case report.
        Neurology. 2003; 61: 419
        • Bona J.R.
        Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series.
        J. Clin. Psychopharmacol. 2006; 26: 215-216
        • Konitsiotis S.
        • Pappa S.
        • Mantas C.
        • Mavreas V.
        Levetiracetam in tardive dyskinesia: an open label study.
        Mov. Disord. 2006; 21: 1219-1221
        • Meco G.
        • Fabrizio E.
        • Epifanio A.
        • Morgante F.
        • Valente M.
        • Vanacore N.
        • DiRosa A.E.
        • Morgante L.
        Levetiracetam in tardive dyskinesia.
        Clin. Neuropharmacol. 2006; 29: 265-268
        • Woods S.W.
        • Saksa J.R.
        • Baker C.B.
        • Cohen S.J.
        • Tek C.
        Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.
        J. Clin. Psychiatry. 2008; 69: 546-554
        • Giurgea C.
        The “nootropic” approach to the pharmacology of the integrative activity of the brain.
        Cond. Reflex. 1973; 8: 108-115
        • Nickolson V.J.
        • Wolthuis O.L.
        Effect of the acquisition-enhancing drug piracetam on rat cerebral energy metabolism. Comparison with naftidrofuryl and methamphetamine.
        Biochem. Pharmacol. 1976; 25: 2241-2244
        • Grau M.
        • Montero J.L.
        • Balasch J.
        Effect of piracetam on electrocorticogram and local cerebral glucose utilization in the rat.
        Gen. Pharmacol. 1987; 18: 205-211
        • Pilch H.
        • Muller W.E.
        Piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice.
        Psychopharmacology. 1988; 94: 74-78
        • Stoll L.
        • Schubert T.
        • Müller W.E.
        Age-related deficits of central muscarinic cholinergic receptor function in the mouse: partial restoration by chronic piracetam treatment.
        Neurobiol. Aging. 1992; 13: 39-44
        • Pranzatelli M.R.
        Effect of antiepileptic and antimyoclonic drugs on serotonin receptors in vitro.
        Epilepsia. 1988; 29: 412-419
        • Olpe H.R.
        • Steinmann M.W.
        The effect of vincamine, hydergine and piracetam on the firing rate of locus coeruleus neurons.
        J. Neural Transm. 1982; 55: 101-109
        • Brandão F.
        • Cadete-Leite A.
        • Andrade J.P.
        • Madeira M.D.
        • Paula-Barbosa M.M.
        Piracetam promotes mossy fiber synaptic reorganization in rats withdrawn from alcohol.
        Alcohol. 1996; 13: 239-249
        • Chaturvedi S.K.
        Piracetam for drug-induced dyskinesia.
        J. Clin. Psychiatry. 1987; 48: 255
        • Fehr C.
        • Dahmen N.
        • Klawe C.
        • Eicke M.
        • Szegedi A.
        Piracetam in the treatment of tardive dyskinesia and akathisia: a case report.
        J. Clin. Psychopharmacol. 2001; 21: 248-249
        • Libov I.
        • Miodownik C.
        • Bersudsky Y.
        • Dwolatzky T.
        Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled cross-over study.
        J. Clin. Psychiatry. 2007; 68: 1031-1037
        • Richardson M.A.
        • Reilly M.A.
        • Read L.L.
        • Flynn C.J.
        • Suckow R.F.
        • Maher T.J.
        • Sziraki I.
        Phenylalanine kinetics are associated with tardive dyskinesia in men but not in women.
        Psychopharmacology. 1999; 143: 347-357
        • Blomstrand E.
        • Newsholme E.A.
        Effect of branched-chain amino acid supplementation on the exercise-induced change in aromatic amino acid concentration in human muscle.
        Acta Physiol. Scand. 1992; 146: 293-298
        • Richardson M.A.
        • Bevans M.L.
        • Weber J.B.
        • Gonzalez J.J.
        • Flynn C.J.
        • Amira L.
        • Read L.L.
        • Suckow R.F.
        • Maher T.J.
        Branched chain amino acids decrease tardive dyskinesia symptoms.
        Psychopharmacology. 1999; 143: 358-364
        • Richardson M.A.
        • Small A.M.
        • Read L.L.
        • Chao H.M.
        • Clelland J.D.
        Branched chain amino acid treatment of tardive dyskinesia in children and adolescents.
        J. Clin. Psychiatry. 2004; 65: 92-96
        • Richardson M.A.
        • Bevans M.L.
        • Read L.L.
        • Chao H.M.
        • Clelland J.D.
        • Suckow R.F.
        • Maher T.J.
        • Citrome L.
        Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men.
        Am. J. Psychiatry. 2003; 160: 1117-1124
        • Hatcher-Martin J.M.
        • Armstrong K.A.
        • Scorr L.M.
        • Factor S.A.
        Propranolol therapy for tardive dyskinesia: a retrospective examination.
        Parkinsonism Relat. Disord. 2016; 32: 124-126
        • Pirazzini M.
        • Rossetto O.
        • Eleopra R.
        • Montecucco C.
        Botulinum neurotoxins: biology, pharmacology, and toxicology.
        Pharmacol. Rev. 2017; 69: 200-235
        • van Harten P.N.
        • Hovestadt A.
        Botulinum toxin as a treatment for tardive dyskinesia.
        Mov. Disord. 2006; 21: 1276-1277
        • Hennings J.M.H.
        • Krause E.
        • Bötzel K.
        • Wetter T.C.
        Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature.
        Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2008; 32: 1167-1171
        • Tschopp L.
        • Salazar Z.
        • Micheli F.
        Botulinum toxin in painful tardive dyskinesia.
        Clin. Neuropharmacol. 2009; 32: 165-166
        • Beckmann Y.Y.
        • Seçil Y.
        • Saka S.
        • Kuserli A.
        • Çiftçi Y.
        Treatment of intractable tardive lingual dyskinesia with botulinum toxin.
        J. Clin. Psychopharmacol. 2011; 31: 250-251
        • Truong D.D.
        • Hermanowicz N.
        • Rontal M.
        Botulinum toxin in treatment of tardive dyskinetic syndrome.
        J. Clin. Psychopharmacol. 1990; 10: 438-439
        • Chatterjee A.
        • Forrest Gordon M.
        • Giladi N.
        • Trosch R.
        Botulinum toxin in the treatment of tardive dystonia.
        J. Clin. Psychopharmacol. 1997; 17: 497-498
        • Esper C.D.
        • Freeman A.
        • Factor S.A.
        Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy.
        Parkinsonism Relat. Disord. 2010; 16: 438-441
        • Tarsy D.
        • Kaufman D.
        • Sethi K.D.
        • Rivner M.H.
        • Molho E.
        • Factor S.
        An open-label study of botulinum toxin A for treatment of tardive dystonia.
        Clin. Neuropharmacol. 1997; 20: 90-93
        • Rapaport A.
        • Sadeh M.
        • Stein D.
        • Levine J.
        • Sirota P.
        • Mosheva T.
        • Stir S.
        • Elitzur A.
        • Reznik I.
        • Geva D.
        • Rabey J.M.
        Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia.
        Mov. Disord. 2000; 15: 352-355
        • Slotema C.W.
        • van Harten P.N.
        • Bruggeman R.
        • Hoek H.W.
        Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study.
        Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008; 32: 507-509
        • Price T.R.
        • Levin R.
        The effects of electroconvulsive therapy on tardive dyskinesia.
        Am. J. Psychiatry. 1978; 135: 991-993
        • Chacko R.C.
        • Root L.
        ECT and tardive dyskinesia: two cases and a review.
        J. Clin. Psychiatry. 1983; 44: 265-266
        • Kwentus J.A.
        • Schulz S.C.
        • Hart R.P.
        Tardive dystonia, catatonia, and electroconvulsive therapy.
        J. Nerv. Ment. Dis. 1984; 172: 171-173
        • Gosek E.
        • Weller R.A.
        Improvement of tardive dyskinesia associated with electroconvulsive therapy.
        J. Nerv. Ment. Dis. 1988; 176: 120-122
        • Malek-Ahmadi P.
        • Weddige R.L.
        Tardive dyskinesia and electroconvulsive therapy.
        Convuls. Ther. 1988; 4: 328-331
        • Hay D.P.
        • Hay L.
        • Blackwell B.
        • Spiro H.R.
        ECT and tardive dyskinesia.
        J. Geriatr. Psychiatry Neurol. 1990; 3: 106-109
        • Besson J.A.
        • Palin A.N.
        Tardive dyskinesia, depression and ECT.
        Br. J. Psychiatry. 1991; 159: 446
        • Nobuhara K.
        • Matsuda S.
        • Okugawa G.
        • Tamagaki C.
        • Kinoshita T.
        Successful electroconvulsive treatment of depression associated with a marked reduction in the symptoms of tardive dyskinesia.
        J. ECT. 2004; 20: 262-263
        • Sienaert P.
        • Peuskens J.
        Remission of tardive dystonia (blepharospasm) after electroconvulsive therapy in a patient with treatment-refractory schizophrenia.
        J. ECT. 2005; 21: 132-134
        • Peng L.-Y.
        • Lee Y.
        • Lin P.-Y.
        Electroconvulsive therapy for a patient with persistent tardive dyskinesia.
        J. ECT. 2013; 29e52–e54
        • Holcomb H.H.
        • Sternberg D.E.
        • Heninger G.R.
        Effects of electroconvulsive therapy on mood, parkinsonism, and tardive dyskinesia in a depressed patient: ECT and dopamine systems.
        Biol. Psychiatry. 1983; 18: 865-873
        • Roth S.D.
        • Mukherjee S.
        • Sackeim H.A.
        Electroconvulsive therapy in a patient with mania, parkinsonism, and tardive dyskinesia.
        Convuls. Ther. 1988; 4: 92-97
        • Asnis G.M.
        • Leopold M.A.
        A single-blind study of ECT in patients with tardive dyskinesia.
        Am. J. Psychiatry. 1978; 135: 1235-1237
        • Yassa R.
        • Hoffman H.
        • Canakis M.
        The effect of electroconvulsive therapy on tardive dyskinesia: a prospective study.
        Convuls. Ther. 1990; 6: 194-198
        • Yasui-Furukori N.
        • Nakamura K.
        • Katagai H.
        • Kaneko S.
        The effects of electroconvulsive therapy on tardive dystonia or dyskinesia induced by psychotropic medication: a retrospective study.
        Neuropsychiatr. Dis. Treat. 2014; 10: 1209-1212